Bivalirudin during primary PCI in acute myocardial infarction.
By G. Stone, B. Witzenbichler, G. Guagliumi, J. Peruga, B. Brodie, Dariusz Dudek, R. Kornowski, Franz Hartmann, B. J. Gersh, S. Pocock and 5 more. New England Journal of Medicine, 2008
1,872 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Hematology, Surgery
View Paper: https://www.semanticscholar.org/paper/9c441d23c8a692199b777952f051f05efe9561f9
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
In Surgery
Citations in the corpus
- ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. (2012, neutral): “One large open-label trial demonstrated the superiority of bivalirudin over the combination of UFH + GP IIb/IIIa inhibitor,(123) a benefit driven by a marked reduction in bleeding, associated with an initial increase in stent thrombosis, which disappeared after 30 days.(124) Importantly, that study ”
- 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST‐Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update) (2009, methodology): “In STEMI patients undergoing PCI who are at high risk of bleeding, bivalirudin anticoagulation is reasonable.(9) (Level of Evidence: B) New recommendation 2009 Focused Updates: STEMI and PCI Guidelines E39”
- 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. (2013, background): “Bivalirudin in this setting may provide a long-term survival benefit related to decreased bleeding but with a higher risk of early stent thrombosis.(248)”